There are 2867 resources available
LBA26 - BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
Presenter: Josep Tabernero
Session: Mini Oral session: GI, lower digestive
Resources:
Abstract
Slides
Webcast
Introduction and scientific background
Presenter: Pasi Jänne
Session: Creating a new stage between early and metastatic cancers: Illustration with lung cancers
Resources:
Slides
Webcast
TILs
Presenter: Inge-Marie Svane
Session: Cellular therapies for solid tumours
Resources:
Slides
Webcast
1489MO - A phase Ib/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial
Presenter: Cesar Serrano
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
624MO - Retrospective analysis of clinical value of ctDNA in newly diagnosed diffuse large B cell lymphoma
Presenter: Tao Guan
Session: Mini Oral session: Haematological malignancies
Resources:
Abstract
651O - Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
Presenter: Marcin Dzienis
Session: Proffered Paper session: Head & neck cancer
Resources:
Abstract
Slides
Webcast
930MO - PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
Presenter: Solange Peters
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA27 - Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC
Presenter: John Strickler
Session: Mini Oral session: GI, lower digestive
Resources:
Abstract
Slides
Webcast
LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
Presenter: Jonathan Rosenberg
Session: Proffered Paper session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Novel technologies embracing blood-based biomarkers for early detection
Presenter: Alexander Frankell
Session: Creating a new stage between early and metastatic cancers: Illustration with lung cancers
Resources:
Slides
Webcast